Compare TPH & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPH | APLS |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | N/A | 2017 |
| Metric | TPH | APLS |
|---|---|---|
| Price | $32.92 | $25.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 19 |
| Target Price | ★ $40.25 | $33.11 |
| AVG Volume (30 Days) | 813.8K | ★ 2.2M |
| Earning Date | 10-23-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.42 | 0.36 |
| Revenue | ★ $3,751,941,000.00 | $1,016,397,000.00 |
| Revenue This Year | N/A | $29.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $9.87 | $70.45 |
| Revenue Growth | N/A | ★ 42.11 |
| 52 Week Low | $27.90 | $16.10 |
| 52 Week High | $40.51 | $35.71 |
| Indicator | TPH | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 48.90 | 67.38 |
| Support Level | $32.30 | $24.45 |
| Resistance Level | $34.50 | $25.52 |
| Average True Range (ATR) | 0.79 | 1.00 |
| MACD | -0.03 | 0.53 |
| Stochastic Oscillator | 24.71 | 94.89 |
Tri Pointe Homes Inc is an American construction company that focuses on residential construction. The company is engaged in the design, construction, and sale of single-family attached and detached homes in different states across the United States. Its operations are organized into two principal businesses: homebuilding. which generates key revenue, and financial services. The homebuilding business has three reportable operating segments, based on the geographical layout of the markets, and includes West region, Central region, and East region. The company's financial services operation is comprised of its Tri Pointe Connect mortgage financing operations, Tri Pointe Assurance title and escrow services operations, and Tri Pointe Advantage property and casualty insurance agency operations.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.